Genomic Health (GHDX) Reports Q2 Loss of $0.15, Tops Street by 3c
More News related to GHDX
- Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
- Thomas Weisel Upgrades Genomic Health (GHDX) to Overweight
- Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
- Oncotype DX(R) Guides Individualized Treatment Decisions for More Than 100,000 Breast Cancer Patients Worldwide
- Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting
Genomic Health, Inc. (Nasdaq: GHDX) reports a Q2 loss of $0.15, 3 cents better than the analyst estimate of ($0.18). Revenues for the quarter were $27.8 million, versus the consensus of $25.84 million.
Related Categories
EarningsStocks Mentioned
-0.82Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
